{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+placebo+capsules&page=3",
    "query": {
      "intervention": "Oral placebo capsules",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 2670,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+placebo+capsules&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+placebo+capsules&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T12:28:41.069Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02561702",
      "title": "Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Charcot Marie Tooth Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Mexiletine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-09",
      "completion_date": "2016-12-31",
      "has_results": true,
      "last_update_posted_date": "2018-03-26",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561702"
    },
    {
      "nct_id": "NCT00297167",
      "title": "Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Exocrine Pancreatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "EUR-1008 (APT-1008)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2006-05",
      "completion_date": "2006-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 1,
      "location_summary": "Tyler, Texas",
      "locations": [
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00297167"
    },
    {
      "nct_id": "NCT01396161",
      "title": "A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PF-05175157 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2011-07",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01396161"
    },
    {
      "nct_id": "NCT01106651",
      "title": "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Antihyperglycemic agent(s)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 716,
      "start_date": "2010-06",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 34,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Citrus Heights",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106651"
    },
    {
      "nct_id": "NCT01147666",
      "title": "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 161,
      "start_date": "2010-05-17",
      "completion_date": "2012-10-15",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 25,
      "location_summary": "Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147666"
    },
    {
      "nct_id": "NCT03467152",
      "title": "Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Irsenontrine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 326,
      "start_date": "2018-05-04",
      "completion_date": "2020-04-15",
      "has_results": true,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 25,
      "location_summary": "Sun City, Arizona • Anaheim, California • Fountain Valley, California + 20 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03467152"
    },
    {
      "nct_id": "NCT04093024",
      "title": "A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2019-12-03",
      "completion_date": "2022-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093024"
    },
    {
      "nct_id": "NCT07181382",
      "title": "Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension Associated With Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Seralutinib",
          "type": "DRUG"
        },
        {
          "name": "Generic Dry Powder Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GB002, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 480,
      "start_date": "2026-02",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 3,
      "location_summary": "Fresno, California • Albuquerque, New Mexico • Richmond, Virginia",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07181382"
    },
    {
      "nct_id": "NCT01191723",
      "title": "QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MAP0004",
          "type": "DRUG"
        },
        {
          "name": "Inhaler Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2010-08",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-01-09",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191723"
    },
    {
      "nct_id": "NCT02176486",
      "title": "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-06-09",
      "completion_date": "2018-01-19",
      "has_results": true,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-10-08T12:28:41.069Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176486"
    }
  ]
}